Fang-Pei Chang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Fang-Pei Chang has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Chen-Hsin Albert Yu
Institute of Molecular Biology, Academia Sinica
9 shared publications - Cheng-Kai Wang
Genomics Research Center, Academia Sinica, Taipei, Taiwan
9 shared publications - Grace Y. T. Tan
Molecular and Cell Biology, Taiwan International Graduate Program, Academia Sinica and National Defense Medical University, Taipei, Taiwan
9 shared publications - Li-Tzu Cheng
Genomics Research Center, Academia Sinica, Taipei, Taiwan
9 shared publications - Samyuktha Sridharan
Genomics Research Center, Academia Sinica, Taipei, Taiwan
9 shared publications - Tzu-Jou Chen
Department of Chemical Immunology and Proteomics, The Rockefeller University, New York, New York, 10065, USA
9 shared publications
Latest Publications
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from MEX3A Mediates p53 Degradation to Suppress Ferroptosis and Facilitate Ovarian Cancer Tumorigenesis
RNAseq: Gene expression fold-change between sh-MEX3A and sh-Ctrl
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from MEX3A Mediates p53 Degradation to Suppress Ferroptosis and Facilitate Ovarian Cancer Tumorigenesis
RNAseq: Gene expression fold-change between sh-MEX3A and sh-Ctrl
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S1-S5, Table S1 from MEX3A Mediates p53 Degradation to Suppress Ferroptosis and Facilitate Ovarian Cancer Tumorigenesis
Table S1. Short tandem repeat of ovarian teratocarcinoma and clear cell carcinoma cell line. Figure S1. MEX3A expression promoted tumorigenic ability and cell survival in WT p53 OC cells. Figure S2. The p53 pathway was enriched in upregulated genes in MEX3A-depleted OC cells expressing WT p53. Figure S3. Stabilized WT p53 protein in MEX3A-depleted cells was activated. MEX3A did not interact with or affect the level of mutant p53 protein. Figure S4. p53 depletion alone did not significantly affect cell proliferation or cell death in MEX3A expressing WT p53 OC cells. Figure S5. MEX3A and MDM2 in OC.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1-S5, Table S1 from MEX3A Mediates p53 Degradation to Suppress Ferroptosis and Facilitate Ovarian Cancer Tumorigenesis
Table S1. Short tandem repeat of ovarian teratocarcinoma and clear cell carcinoma cell line. Figure S1. MEX3A expression promoted tumorigenic ability and cell survival in WT p53 OC cells. Figure S2. The p53 pathway was enriched in upregulated genes in MEX3A-depleted OC cells expressing WT p53. Figure S3. Stabilized WT p53 protein in MEX3A-depleted cells was activated. MEX3A did not interact with or affect the level of mutant p53 protein. Figure S4. p53 depletion alone did not significantly affect cell proliferation or cell death in MEX3A expressing WT p53 OC cells. Figure S5. MEX3A and MDM2 in OC.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Data from MEX3A Mediates p53 Degradation to Suppress Ferroptosis and Facilitate Ovarian Cancer Tumorigenesis
Epithelial ovarian cancer is a highly heterogeneous and malignant female cancer with an overall low survival rate. Mutations in p53 are prevalent in the major ovarian cancer histotype, high-grade serous ovarian carcinoma (HGSOC), while p53 mutations are much less frequent in other ovarian cancer subtypes, particularly in ovarian clear cell carcinoma (OCCC). Advanced stage OCCC with wild-type (WT) p53 has a worse prognosis and increased drug resistance, metastasis, and recurrence than HGSOC. The mechanisms responsible for driving the aggressiveness of WT p53-expressing ovarian cancer remain poorly understood. Here, we found that upregulation of MEX3A, a dual-function protein containing a RING finger domain and an RNA-binding domain, was critical for tumorigenesis in WT p53-expressing ovarian cancer. MEX3A overexpression enhanced the growth and clonogenicity of OCCC cell lines. In contrast, depletion of MEX3A in OCCC cells, as well as ovarian teratocarcinoma cells, reduced cell survival and proliferative ability. MEX3A depletion also inhibited tumor growth and prolonged survival in orthotopic xenograft models. MEX3A depletion did not alter p53 mRNA level but did increase p53 protein stability. MEX3A-mediated p53 protein degradation was crucial to suppress ferroptosis and enhance tumorigenesis. Consistently, p53 knockdown reversed the effects of MEX3A depletion. Together, our observations identified MEX3A as an important oncogenic factor promoting tumorigenesis in ovarian cancer cells expressing WT p53.Significance:Degradation of p53 mediated by MEX3A drives ovarian cancer growth by circumventing p53 tumor suppressive functions, suggesting targeting MEX3A as a potential strategy for treating of ovarian cancer expressing WT p53.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from MEX3A Mediates p53 Degradation to Suppress Ferroptosis and Facilitate Ovarian Cancer Tumorigenesis
Epithelial ovarian cancer is a highly heterogeneous and malignant female cancer with an overall low survival rate. Mutations in p53 are prevalent in the major ovarian cancer histotype, high-grade serous ovarian carcinoma (HGSOC), while p53 mutations are much less frequent in other ovarian cancer subtypes, particularly in ovarian clear cell carcinoma (OCCC). Advanced stage OCCC with wild-type (WT) p53 has a worse prognosis and increased drug resistance, metastasis, and recurrence than HGSOC. The mechanisms responsible for driving the aggressiveness of WT p53-expressing ovarian cancer remain poorly understood. Here, we found that upregulation of MEX3A, a dual-function protein containing a RING finger domain and an RNA-binding domain, was critical for tumorigenesis in WT p53-expressing ovarian cancer. MEX3A overexpression enhanced the growth and clonogenicity of OCCC cell lines. In contrast, depletion of MEX3A in OCCC cells, as well as ovarian teratocarcinoma cells, reduced cell survival and proliferative ability. MEX3A depletion also inhibited tumor growth and prolonged survival in orthotopic xenograft models. MEX3A depletion did not alter p53 mRNA level but did increase p53 protein stability. MEX3A-mediated p53 protein degradation was crucial to suppress ferroptosis and enhance tumorigenesis. Consistently, p53 knockdown reversed the effects of MEX3A depletion. Together, our observations identified MEX3A as an important oncogenic factor promoting tumorigenesis in ovarian cancer cells expressing WT p53.Significance:Degradation of p53 mediated by MEX3A drives ovarian cancer growth by circumventing p53 tumor suppressive functions, suggesting targeting MEX3A as a potential strategy for treating of ovarian cancer expressing WT p53.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from MEX3A Mediates p53 Degradation to Suppress Ferroptosis and Facilitate Ovarian Cancer Tumorigenesis
Epithelial ovarian cancer is a highly heterogeneous and malignant female cancer with an overall low survival rate. Mutations in p53 are prevalent in the major ovarian cancer histotype, high-grade serous ovarian carcinoma (HGSOC), while p53 mutations are much less frequent in other ovarian cancer subtypes, particularly in ovarian clear cell carcinoma (OCCC). Advanced stage OCCC with wild-type (WT) p53 has a worse prognosis and increased drug resistance, metastasis, and recurrence than HGSOC. The mechanisms responsible for driving the aggressiveness of WT p53-expressing ovarian cancer remain poorly understood. Here, we found that upregulation of MEX3A, a dual-function protein containing a RING finger domain and an RNA-binding domain, was critical for tumorigenesis in WT p53-expressing ovarian cancer. MEX3A overexpression enhanced the growth and clonogenicity of OCCC cell lines. In contrast, depletion of MEX3A in OCCC cells, as well as ovarian teratocarcinoma cells, reduced cell survival and proliferative ability. MEX3A depletion also inhibited tumor growth and prolonged survival in orthotopic xenograft models. MEX3A depletion did not alter p53 mRNA level but did increase p53 protein stability. MEX3A-mediated p53 protein degradation was crucial to suppress ferroptosis and enhance tumorigenesis. Consistently, p53 knockdown reversed the effects of MEX3A depletion. Together, our observations identified MEX3A as an important oncogenic factor promoting tumorigenesis in ovarian cancer cells expressing WT p53.Significance:Degradation of p53 mediated by MEX3A drives ovarian cancer growth by circumventing p53 tumor suppressive functions, suggesting targeting MEX3A as a potential strategy for treating of ovarian cancer expressing WT p53.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from MEX3A Mediates p53 Degradation to Suppress Ferroptosis and Facilitate Ovarian Cancer Tumorigenesis
Epithelial ovarian cancer is a highly heterogeneous and malignant female cancer with an overall low survival rate. Mutations in p53 are prevalent in the major ovarian cancer histotype, high-grade serous ovarian carcinoma (HGSOC), while p53 mutations are much less frequent in other ovarian cancer subtypes, particularly in ovarian clear cell carcinoma (OCCC). Advanced stage OCCC with wild-type (WT) p53 has a worse prognosis and increased drug resistance, metastasis, and recurrence than HGSOC. The mechanisms responsible for driving the aggressiveness of WT p53-expressing ovarian cancer remain poorly understood. Here, we found that upregulation of MEX3A, a dual-function protein containing a RING finger domain and an RNA-binding domain, was critical for tumorigenesis in WT p53-expressing ovarian cancer. MEX3A overexpression enhanced the growth and clonogenicity of OCCC cell lines. In contrast, depletion of MEX3A in OCCC cells, as well as ovarian teratocarcinoma cells, reduced cell survival and proliferative ability. MEX3A depletion also inhibited tumor growth and prolonged survival in orthotopic xenograft models. MEX3A depletion did not alter p53 mRNA level but did increase p53 protein stability. MEX3A-mediated p53 protein degradation was crucial to suppress ferroptosis and enhance tumorigenesis. Consistently, p53 knockdown reversed the effects of MEX3A depletion. Together, our observations identified MEX3A as an important oncogenic factor promoting tumorigenesis in ovarian cancer cells expressing WT p53.Significance:Degradation of p53 mediated by MEX3A drives ovarian cancer growth by circumventing p53 tumor suppressive functions, suggesting targeting MEX3A as a potential strategy for treating of ovarian cancer expressing WT p53.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Table S2 from MEX3A Mediates p53 Degradation to Suppress Ferroptosis and Facilitate Ovarian Cancer Tumorigenesis
RNAseq: Gene expression fold-change between sh-MEX3A and sh-Ctrl
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from MEX3A Mediates p53 Degradation to Suppress Ferroptosis and Facilitate Ovarian Cancer Tumorigenesis
RNAseq: Gene expression fold-change between sh-MEX3A and sh-Ctrl
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S1-S5, Table S1 from MEX3A Mediates p53 Degradation to Suppress Ferroptosis and Facilitate Ovarian Cancer Tumorigenesis
Table S1. Short tandem repeat of ovarian teratocarcinoma and clear cell carcinoma cell line. Figure S1. MEX3A expression promoted tumorigenic ability and cell survival in WT p53 OC cells. Figure S2. The p53 pathway was enriched in upregulated genes in MEX3A-depleted OC cells expressing WT p53. Figure S3. Stabilized WT p53 protein in MEX3A-depleted cells was activated. MEX3A did not interact with or affect the level of mutant p53 protein. Figure S4. p53 depletion alone did not significantly affect cell proliferation or cell death in MEX3A expressing WT p53 OC cells. Figure S5. MEX3A and MDM2 in OC.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1-S5, Table S1 from MEX3A Mediates p53 Degradation to Suppress Ferroptosis and Facilitate Ovarian Cancer Tumorigenesis
Table S1. Short tandem repeat of ovarian teratocarcinoma and clear cell carcinoma cell line. Figure S1. MEX3A expression promoted tumorigenic ability and cell survival in WT p53 OC cells. Figure S2. The p53 pathway was enriched in upregulated genes in MEX3A-depleted OC cells expressing WT p53. Figure S3. Stabilized WT p53 protein in MEX3A-depleted cells was activated. MEX3A did not interact with or affect the level of mutant p53 protein. Figure S4. p53 depletion alone did not significantly affect cell proliferation or cell death in MEX3A expressing WT p53 OC cells. Figure S5. MEX3A and MDM2 in OC.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Table S2 from MEX3A Mediates p53 Degradation to Suppress Ferroptosis and Facilitate Ovarian Cancer Tumorigenesis
RNAseq: Gene expression fold-change between sh-MEX3A and sh-Ctrl
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from MEX3A Mediates p53 Degradation to Suppress Ferroptosis and Facilitate Ovarian Cancer Tumorigenesis
RNAseq: Gene expression fold-change between sh-MEX3A and sh-Ctrl
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S1-S5, Table S1 from MEX3A Mediates p53 Degradation to Suppress Ferroptosis and Facilitate Ovarian Cancer Tumorigenesis
Table S1. Short tandem repeat of ovarian teratocarcinoma and clear cell carcinoma cell line. Figure S1. MEX3A expression promoted tumorigenic ability and cell survival in WT p53 OC cells. Figure S2. The p53 pathway was enriched in upregulated genes in MEX3A-depleted OC cells expressing WT p53. Figure S3. Stabilized WT p53 protein in MEX3A-depleted cells was activated. MEX3A did not interact with or affect the level of mutant p53 protein. Figure S4. p53 depletion alone did not significantly affect cell proliferation or cell death in MEX3A expressing WT p53 OC cells. Figure S5. MEX3A and MDM2 in OC.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1-S5, Table S1 from MEX3A Mediates p53 Degradation to Suppress Ferroptosis and Facilitate Ovarian Cancer Tumorigenesis
Table S1. Short tandem repeat of ovarian teratocarcinoma and clear cell carcinoma cell line. Figure S1. MEX3A expression promoted tumorigenic ability and cell survival in WT p53 OC cells. Figure S2. The p53 pathway was enriched in upregulated genes in MEX3A-depleted OC cells expressing WT p53. Figure S3. Stabilized WT p53 protein in MEX3A-depleted cells was activated. MEX3A did not interact with or affect the level of mutant p53 protein. Figure S4. p53 depletion alone did not significantly affect cell proliferation or cell death in MEX3A expressing WT p53 OC cells. Figure S5. MEX3A and MDM2 in OC.
- Open Access
- 9 November 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 83 (2) , 251-263
MEX3A Mediates p53 Degradation to Suppress Ferroptosis and Facilitate Ovarian Cancer Tumorigenesis
Epithelial ovarian cancer is a highly heterogeneous and malignant female cancer with an overall low survival rate. Mutations in p53 are prevalent in the major ovarian cancer histotype, high-grade serous ovarian carcinoma (HGSOC), while p53 mutations are much less frequent in other ovarian cancer subtypes, particularly in ovarian clear cell carcinoma (OCCC). Advanced stage OCCC with wild-type (WT) p53 has a worse prognosis and increased drug resistance, metastasis, and recurrence than HGSOC. The mechanisms responsible for driving the aggressiveness of WT p53-expressing ovarian cancer remain poorly understood. Here, we found that upregulation of MEX3A, a dual-function protein containing a RING finger domain and an RNA-binding domain, was critical for tumorigenesis in WT p53-expressing ovarian cancer. MEX3A overexpression enhanced the growth and clonogenicity of OCCC cell lines. In contrast, depletion of MEX3A in OCCC cells, as well as ovarian teratocarcinoma cells, reduced cell survival and proliferative ability. MEX3A depletion also inhibited tumor growth and prolonged survival in orthotopic xenograft models. MEX3A depletion did not alter p53 mRNA level but did increase p53 protein stability. MEX3A-mediated p53 protein degradation was crucial to suppress ferroptosis and enhance tumorigenesis. Consistently, p53 knockdown reversed the effects of MEX3A depletion. Together, our observations identified MEX3A as an important oncogenic factor promoting tumorigenesis in ovarian cancer cells expressing WT p53. Significance: Degradation of p53 mediated by MEX3A drives ovarian cancer growth by circumventing p53 tumor suppressive functions, suggesting targeting MEX3A as a potential strategy for treating of ovarian cancer expressing WT p53.
- 9 November 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 83 (2) , 251-263
Open AccessMEX3A Mediates p53 Degradation to Suppress Ferroptosis and Facilitate Ovarian Cancer Tumorigenesis
Epithelial ovarian cancer is a highly heterogeneous and malignant female cancer with an overall low survival rate. Mutations in p53 are prevalent in the major ovarian cancer histotype, high-grade serous ovarian carcinoma (HGSOC), while p53 mutations are much less frequent in other ovarian cancer subtypes, particularly in ovarian clear cell carcinoma (OCCC). Advanced stage OCCC with wild-type (WT) p53 has a worse prognosis and increased drug resistance, metastasis, and recurrence than HGSOC. The mechanisms responsible for driving the aggressiveness of WT p53-expressing ovarian cancer remain poorly understood. Here, we found that upregulation of MEX3A, a dual-function protein containing a RING finger domain and an RNA-binding domain, was critical for tumorigenesis in WT p53-expressing ovarian cancer. MEX3A overexpression enhanced the growth and clonogenicity of OCCC cell lines. In contrast, depletion of MEX3A in OCCC cells, as well as ovarian teratocarcinoma cells, reduced cell survival and proliferative ability. MEX3A depletion also inhibited tumor growth and prolonged survival in orthotopic xenograft models. MEX3A depletion did not alter p53 mRNA level but did increase p53 protein stability. MEX3A-mediated p53 protein degradation was crucial to suppress ferroptosis and enhance tumorigenesis. Consistently, p53 knockdown reversed the effects of MEX3A depletion. Together, our observations identified MEX3A as an important oncogenic factor promoting tumorigenesis in ovarian cancer cells expressing WT p53. Significance: Degradation of p53 mediated by MEX3A drives ovarian cancer growth by circumventing p53 tumor suppressive functions, suggesting targeting MEX3A as a potential strategy for treating of ovarian cancer expressing WT p53.